RxDoctor Payments Data

Kiranpreet Parmar, MD

Gastroenterology · Brooklyn, NYNPI 1396735874

Payments from drug & device makers

$36,246in general payments, 2019–2025

Across 647 payments — averaging $56.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$25K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$1K
  • Bristol Myers Squibb$926
  • plus $5K from 31 others

What the payments were for

  • Travel & lodging$2961%
  • Food & beverage$11,32331%
  • Education$210%
  • Other$24,60668%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,246 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$494,812
Medicare patients
1,005
Services billed
2,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab13$118,701
LinzessLinaclotide58$55,500
CreonLipase/Protease/Amylase31$54,659
ZenpepLipase/Protease/Amylase22$51,194
XifaxanRifaximin18$46,303
VemlidyTenofovir Alafenamide12$25,363
Chlordiazepoxide-ClidiniumChlordiazepoxide/Clidinium Br15$20,179
Mesalamine47$18,565
SutabSod Sulf/Pot Chloride/Mag Sulf89$14,236
AprisoMesalamine17$11,396
Famotidine585$9,722
ClenpiqSod Picosulf/Mag Ox/Citric Ac52$8,835
Dexlansoprazole DrDexlansoprazole37$8,350
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag46$5,469
Omeprazole468$5,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$1,745$118,70113 claims
AbbVieLinzess, Creon$1,555$110,15989 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Apriso$1,368$57,69935 claims
Aimmune Therapeutics, Inc.Zenpep$149$51,19422 claims
GileadVemlidy$1,144$25,36312 claims
Braintree Laboratories, Inc.Sutab, Suflave$101$19,705135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →